Strengths and limitations: This section does not accomplish the author's guideline: it should containing up to five short bullet points, no longer than one sentence each, that relate specifically to the methods. Introduction: Page 6, second paragraph: I think it should be explained more extensively. Methods and analysis: As recommend the journal, PRISMA-P must be followed and the check-list should be included as complementary material (Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.) Is there any exclusion criterion for population? Please, inform not only of characteristics of the interventions but also of comparisons. Please, could you explain how the classification system for the severity of PUs? How do you intend to manage the limitations regarding to languages. Which criteria was used to choose the eligibility form? Was it based on previous work? How it is planned to assure the accuracy of the selected search strategy? Will it be review by an specialistic librarian? According standards for systematic reviews: authors should determine whether any of the selected studies do not report some of the outcomes of interest Which criteria will be used to be included the studies in the metaanalysis? Will it be performanced any technique to evaluate the interobserver bias/ consistency? Which form will be used for data extraction? There was it used in previous work? How data from extraction will be managed (for example, by a specific software)? Which confusors or potential effect modifiers will be take into account? How l it will be manage the analysis of possible intervention harms? How the quality evaluation will be presented in the paper? I do not understand the sentence in page 11, line 7-8: "Trials will be…" Please, state the way of reporting review findings Ethics and dissemination: further implications should be stated: clinicals, for administration, etc. References: Review reference 2, 13, 26, 28. The references should be up-date. 80% should be from last 10 years and 50% from last 5 years
VERSION 1 -AUTHOR RESPONSE
Reviewers' comments Reviewer 1 The protocol is well described although perhaps an additional paragraph introducing Thank you for your positive comment. As you suggested, a paragraph that introduces the network meta-anlaysis has now been added to the network meta-analysis to the reader may be helpful. introduction section. Please refer to page 6, line 57-60 and page 7, line 4 for details. The authors note that they will contact guideline producing associations but only mention NPUAP and the EPUAP? Perhaps a wider trawl of national pressure ulcer guidelines might add to the project?
As per your advice, more relevant associations such as PPPIA, Chinese Nursing Association, Japanese Society for Pressure Ulcers have now been included (page 9, line 44-50 ).
Reviewer 2 Writing style: It should be reviewed by an English speaker as well as checking some typos.
Agreed. Associate Professor Karen V. Lamb, an English speaker, from College of Nursing, Rush University, USA had reviewed the manuscript from English language perspective (please refer to the acknowledgement section for details). page 4, line 26-27: The sentence should be more specific by using less vague expressions ("numerous", "various").
As per your suggestion, the sentence has now been restructured as: "In the absence of large randomized controlled trials (RCT) that compare all interventions for preventing PU in ICUs, uncertainty remains about what is the best practice for PU management in adult ICUs". ethics and dissemination: further implications should be stated: clinicals, for administration, etc.
Agreed. The clinical implications will include informing healthcare providers about the selection of more appropriate prevention PU measures which may ultimately lead to a reduction in health care costs and improved patients outcomes in adult ICUs (page 5, line 51-57). In the protocol number, the registry agency has to be indicated.
Agreed. The registry agency has now been included into the Protocol registration number: PROSPERO CRD42018085562; available at: http://www.crd.york.ac.uk/PROSPERO/display_rec ord.php?ID=CRD42018085562 Strengths and limitations: This section does not accomplish the author's guideline: it should containing up to five short bullet points, no longer than one sentence each, that relate specifically to the methods.
Thanks for your valid point. This section has now been revised in accordance with the author's guideline. Please refer to page 5, line 31-60 and page 6, line 4 for details.
Introduction: Page 6, second paragraph: I think it should be explained more extensively.
Thank you. The paragraph has now been further elaborated as suggested.
Methods and analysis:
As recommend the journal, PRISMA-P must be followed and the check-list should be included as complementary material (Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.)
As per your suggestion, the PRISMA-P checklist has now been included as a complementary material.
Is there any exclusion criterion for population? Yes, exclusion criterion will be patients who are younger than 18 years or not admitted to the adult ICU. Please, inform not only of characteristics of the interventions but also of comparisons. The literature has shown the dominance of English in international scientific publications with almost 80% research findings reported in English.
[1] Considering the dramatic increase in scientific publications in Chinese-language journals,[2] encompassing both English and Chinese articles may allow us to achieve a descent coverage. Nevertheless, we understand that overlooking non-English and non-Chinese articles may lead to biases and gaps in our understanding of the topic, which is one of our study limitations. Which criteria was used to choose the eligibility form? Was it based on previous work?
The development of the eligibility form was informed by the relevant study [3] . The form was reviewed by a panel of experts comprising librarian, ICU clinical nurse specialists, wound care nurse specialists and subsequently piloted by the key investigators. How it is planned to assure the accuracy of the selected search strategy? Will it be review by a specialistic librarian?
Yes, an experienced librarian will be helping us to review the selected search strategy. Our approaches to assure the accuracy of the selected search strategy also include pre-training, independent search and team consultations. According standards for systematic reviews: authors should determine whether any of the selected studies do not report some of the outcomes of interest.
You are correct. We will determine whether any of the selected studies do not report some of the outcomes of interest (please refer to page 11, line 1-7). Which criteria will be used to be included the studies in the meta-analysis?
The selection criteria have been listed under the subheading:'Selection of studies'. Please refer to page 10, line 4-34. Will it be performanced any technique to evaluate the inter-observer bias/ consistency? How data from extraction will be managed (for example, by a specific software)?
Yes. All investigators will be properly trained prior to the commencement of the data screening. Additionally, Rayyan online literature management software (https://rayyan.qcri.org) will be introduced to screen and manage literature. As described on page 10, after members of the team independently screen a random sample of 50 citations, interobserver agreement for the selected studies will be calculated using Kappa test, if Kappa value < 0.75 then a second round of training will be conducted. Which confusors or potential effect modifiers will be taken into account?
Commonly known potential effect modifiers including the mean age of the participants, the risk score of PU, the length of ICU stay will be taken into account. Please refer to Page 12, line 56-60 for details. Which form will be used for data extraction? There was it used in previous work?
A structured data extraction form will be developed by our research team. The form will be independently pilot tested by members of the team prior to its application. Please refer to Page 10, line 40-51 for details. How it will be manage the analysis of possible intervention harms?
As described on page 9, line 11-14, we will assess the incidence of possible intervention harms. How the quality evaluation will be presented in the paper?
The quality of evidence will be assessed with GRADE and presented in accordance with their level of quality. Please refer to page 14, line11-21 for details. I do not understand the sentence in page 11, line 7-8: "Trials will be…"
The sentence has been removed to improve the clarity. Please, state the way of reporting review findings.
Information regarding the way of reporting review findings has been included Please refer to page 14, line 48-53 for details. Ethics and dissemination: further implications should be stated: clinicals, for administration, etc.
As the same question has been asked before, please refer to information on page 2 of this table for the answer. References: Review reference 2, 13, 26, 28. The references should be up-date. 80% should be from last 10 years and 50% from last 5 years.
Agreed. We have updated our references. In the revised version, more than 65% of the references are within the last 5 years and over 80% are from the last 10 years.
VERSION 2 -REVIEW

REVIEWER
Michael Clark Welsh Wound Innovation Centre, UK REVIEW RETURNED 31-Dec-2018
GENERAL COMMENTS
Thank you for modifying the manuscript following my comments upon the previous submission.
REVIEWER
Marta Lima Serrano
Universidad de Sevilla, Spain REVIEW RETURNED 07-Jan-2019
GENERAL COMMENTS
Dear authors, congratulations, most of the changes were made. However, some of the comment were not accomplished and minor changes are required:
The clinical implications should be included in the specific section: "Ethics and dissemination" Please, review the third bullet in the Strengths and limitations section, there is a typo. Exclusion criteria (for population) are not the opposite to inclusion criteria, they are those characteristics that disqualify subjects which previously met inclusion criteria. They are not defined in the paper and they should be defined if applicable (otherwise it should be stated that they are not applicable)
Limitations regarding languages should be specified in the manuscript. I do not find in the text the response to the following comment: "According standards for systematic reviews: authors should determine whether any of the selected studies do not report some of the outcomes of interest." The authors had included the selection criteria have been listed under the subheading: 'Selection of studies' (page 10, line 4-34.). However, these criteria are for the systematic review, but how about selection criteria for meta-analysis (if applicable)?
The authors should explain in the manuscript how they will be developed the eligibility form The authors should include in the manuscript the search period. I think that I did not explain well with the following comment: "Please, state the way of reporting review findings.", which I wanted to say is that authors should indicated how they will present the results: using graphs, what kind of table, league tables, forest plots Please, specify how the information regarding to risk of bias appraisal will be used in data synthesis.
VERSION 2 -AUTHOR RESPONSE
Reviewer's comments Our responses The clinical implications should be included in the specific section: "Ethics and dissemination"
The clinical implications have been added in the section "Ethics and dissemination" as you suggested. Please refer to page 14 lines 21-24 for details. Please, review the third bullet in the Strengths and limitations section, there is a typo.
The typo has been amended. Thank you.
Exclusion criteria (for population) are not the opposite to inclusion criteria, they are those characteristics that disqualify subjects which previously met inclusion criteria. They are not defined in the paper and they should be defined if applicable (otherwise it should be stated that they are not applicable).
To improve clarity, the following phrase has been included in the text: 'Apart from the age limit, no other exclusion criteria are applicable'. Please refer to page 6 lines 49-52.
Limitations regarding languages should be specified in the manuscript.
As you suggested, limitations regarding languages has been specified in page 8 lines 19-23. I do not find in the text the response to the following comment: "According standards for systematic reviews: authors should determine whether any of the selected studies do not report some of the outcomes of interest."
The information you are looking for has been described on page 10, lines 19-42.
